‘Senn’s specialised experience in peptide improvement and its sturdy buyer relationships complement Granules’ manufacturing energy and international attain’
Granules India hassuccessfully closed beforehand introduced acquisition of Senn Chemical compounds AG, a Swiss-based Contract Growth and Manufacturing Organisation (CDMO), specialising in peptide improvement and manufacturing.
The Hyderabad-based firm had earlier singed a definitive share buy settlement in February 2025, , by way of its wholly-owned Indian subsidiary, Granules Peptides, to accumulate 100 per cent of the fairness of Senn Chemical compounds from the founding Senn household for ₹192.5 crore.
Based over 60 years in the past, Senn Chemical compounds has constructed a robust popularity as a specialist in Liquid-Part Peptide Synthesis (LPPS) and Stable-Part Peptide Synthesis (SPPS), serving innovators and model house owners throughout pharmaceutical, beauty, amino acid spinoff (AAD), and theragnostic markets.
The Senn Chemical compounds model and its operations in Dielsdorf, Switzerland, will function below Granules’ possession, with a dedication to sustaining the corporate’s scientific excellence and buyer focus.
Pivotal step
“The acquisition of Senn Chemical compounds AG marks a pivotal step in Granules’ strategic evolution right into a science and innovation-led organisation. By coming into the quickly rising peptide therapeutics phase and constructing on Senn’s specialised CDMO capabilities, we’re effectively positioned to ship high-quality, next-generation remedies,’‘ Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India stated in a launch on Thursday.
Senn’s specialised experience in peptide improvement and its sturdy buyer relationships complement Granules’ manufacturing energy and international attain, he added.
The acquisition will allow Granules to speed up improvement and manufacturing of GLP-1 receptor agonists and different peptide-based APIs, addressing the rising demand in antidiabetic, anti-obesity, and different next-generation therapeutic areas.
Granules and Senn have already initiated joint improvement actions on this house, with a broader peptide API pipeline deliberate. This transaction additionally marks Granules’ foray into the CDMO house, with Senn’s established CDMO enterprise offering a robust platform for development.
Printed on April 10, 2025